CLINICAL ROLE -
Video
Author(s):
Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.
Interferon Lowers Myelofibrosis Risk in Young Patients With Polycythemia Vera, Essential Thrombocytopenia
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
Anitocabtagene Autoleucel Yields Overall Response Rate of 97% in Patients With Multiple Myeloma
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
Statins May Improve Survival in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib
GPRC5D-Targeted CAR T-Cell Therapy Shows Promise After BCMA Treatment Failure